<unk>  is a monoclonal antibody that is FDA approved for the treatment of advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy and metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include hypertension and diarrhea.
Ramucirumab
Nebacumab
Ustekinumab
Evolocumab
Avelumab
Burosumab
Alirocumab
Sarilumab